Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1776-260X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors ; day:8 ; month:2 ; year:2021 ; pages:1-9
Targeted oncology ; (8.2.2021), 1-9
- Urheber
-
Gassenmaier, Maximilian
Lenders, Max M.
Forschner, Andrea
Leiter-Stöppke, Ulrike
Weide, Benjamin
Garbe, Claus
Eigentler, Thomas K.
Wagner, Nikolaus B.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s11523-021-00792-8
- URN
-
urn:nbn:de:101:1-2021030321534212814655
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:36 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Gassenmaier, Maximilian
- Lenders, Max M.
- Forschner, Andrea
- Leiter-Stöppke, Ulrike
- Weide, Benjamin
- Garbe, Claus
- Eigentler, Thomas K.
- Wagner, Nikolaus B.
- SpringerLink (Online service)
Ähnliche Objekte (12)
S100B and LDH as parameters to monitor the clinical course of patients with advanced melanoma treated with Vemurafenib
Vergleichende Untersuchung zu YKL-40, S100B und LDH als serologische Prognoseparameter bei malignem Melanom
Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase
Optimizing the treatment of BRAF mutant melanoma
Novel combination therapies for BRAF-mutant melanoma
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
The immune-related role of BRAF in melanoma
Clinical significance of BRAF mutations in metastatic melanoma
The role of BRAF V600 mutation in melanoma
B-Raf specific antibody responses in melanoma patients
Gene Expression Signature of BRAF Inhibitor Resistant Melanoma Spheroids
S100B and LDH as parameters to monitor the clinical course of patients with advanced melanoma treated with Vemurafenib
Vergleichende Untersuchung zu YKL-40, S100B und LDH als serologische Prognoseparameter bei malignem Melanom
Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase
Optimizing the treatment of BRAF mutant melanoma
Novel combination therapies for BRAF-mutant melanoma
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
The immune-related role of BRAF in melanoma
Clinical significance of BRAF mutations in metastatic melanoma
The role of BRAF V600 mutation in melanoma
B-Raf specific antibody responses in melanoma patients
Gene Expression Signature of BRAF Inhibitor Resistant Melanoma Spheroids
S100B and LDH as parameters to monitor the clinical course of patients with advanced melanoma treated with Vemurafenib
Vergleichende Untersuchung zu YKL-40, S100B und LDH als serologische Prognoseparameter bei malignem Melanom
Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase
Optimizing the treatment of BRAF mutant melanoma
Novel combination therapies for BRAF-mutant melanoma
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
The immune-related role of BRAF in melanoma
Clinical significance of BRAF mutations in metastatic melanoma
The role of BRAF V600 mutation in melanoma
B-Raf specific antibody responses in melanoma patients